AI-guided computational redesign of the CAR binding domain for enhancing CAR T cell efficacy against CEA-positive solid tumors

Chimeric antigen receptor (CAR) T cell therapy achieves outstanding results in blood cancer treatment, however, lacks behind in solid cancers. Imbalanced CAR signaling may limit long-term T cell functionality: too weak activation leads to inactivity, while overly strong activation causes activation-induced T cell exhaustion. The CAR’s antigen-recognition domain is the initiator of T cell signaling. Artificial intelligence (AI) now enables targeted design of this domain with great potential for improvement.

Prediction of procedural result analysis using computational fluid dynamics of a multicenter, randomized, controlled study to assess Mitral vAlve reconsTrucTion for advancEd insufficiency of functional or iscHemic ORigiN (MATTERHORN Long Term)

The “MATTERHORN Long Term” project compares the long-term therapeutic success of transcatheter mitral valve edge-to-edge repair (M-TEER) with surgical treatment in patients with functional mitral regurgitation. The original MATTERHORN study showed that, after one year, M-TEER was not inferior to surgery. The current project will now examine whether differences in durability, cardiac function, and clinical outcomes emerge over a longer follow-up period.

Immunopeptidome-guided Exploration of Minor Histocompatibility Antigens – Novel Targets to Improve Transplantation Outcome in Acute Myeloid Leukemia

Stem cell transplantation is an important pillar in the treatment of leukemia. An important prerequisite for a successful treatment is the matching of tissue characteristics between donor and recipient. Minor histocompatibility antigens (MiHAs), arising from small genetic differences between donor and recipient and recognized by the immune system, are the key factors that determine how successful a stem cell transplantation is and how serious the side effects are.

BTK Functions in CNS-Compartmentalized Inflammation: Mechanistic Insights from Therapeutic BTK Inhibition in an Animal Model of Progressive Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that causes progressive disability. Recently, a new drug called tolebrutinib became the first treatment to show success in people with secondary progressive MS without disease activity — a form of the disease for which there were few effective treatment options. While the results are promising, the precise mode of action remains unclear.

Subscribe to Scientific Funding